Moore Capital Management LP Has $1.44 Million Stock Position in Replimune Group, Inc. $REPL

Moore Capital Management LP lowered its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 58.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 130,195 shares of the company’s stock after selling 180,929 shares during the quarter. Moore Capital Management LP owned approximately 0.14% of Replimune Group worth $1,441,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in REPL. ProShare Advisors LLC boosted its holdings in Replimune Group by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock valued at $157,000 after acquiring an additional 1,505 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Replimune Group by 4.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after purchasing an additional 1,712 shares during the last quarter. Ballentine Partners LLC grew its position in shares of Replimune Group by 7.8% during the 4th quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock worth $230,000 after buying an additional 1,721 shares during the period. BNP Paribas Financial Markets grew its position in shares of Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after buying an additional 1,879 shares during the period. Finally, Walleye Capital LLC raised its stake in shares of Replimune Group by 3.2% during the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after buying an additional 2,192 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insider Activity

In other news, insider Konstantinos Xynos sold 11,447 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the sale, the insider directly owned 224,215 shares of the company’s stock, valued at $2,908,068.55. This trade represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the sale, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. This trade represents a 5.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 79,124 shares of company stock valued at $1,038,364 in the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a research note on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Replimune Group has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Replimune Group Trading Down 1.3%

NASDAQ REPL opened at $15.30 on Tuesday. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $16.15. The stock’s 50 day moving average price is $11.92 and its two-hundred day moving average price is $8.40. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -4.86 and a beta of 0.88. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, analysts anticipate that Replimune Group, Inc. will post -2.81 earnings per share for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.